Once-Monthly Oral Ibandronate Improves Biomechanical Determinants of Bone Strength in Women with Postmenopausal Osteoporosis | Zendy

E. Michael Lewiecki | Zendy; Tony M. Keaveny | Zendy; David L. Kopperdahl | Zendy; Harry K. Genant | Zendy; Klaus Engelke | Zendy; Thomas Fuerst | Zendy; Alan Kivitz | Zendy; Richard Y. Davies | Zendy; Lorraine A. Fitzpatrick | Zendy

Open Access

Once-Monthly Oral Ibandronate Improves Biomechanical Determinants of Bone Strength in Women with Postmenopausal Osteoporosis

Author(s) -

E. Michael Lewiecki,

Tony M. Keaveny,

David L. Kopperdahl,

Harry K. Genant,

Klaus Engelke,

Thomas Fuerst,

Alan Kivitz,

Richard Y. Davies,

Lorraine A. Fitzpatrick

Publication year - 2008

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2008-1807

Subject(s) - osteoporosis , postmenopausal women , medicine , postmenopausal osteoporosis , physical therapy , dentistry , bone mineral

Bone strength and fracture resistance are determined by bone mineral density (BMD) and structural, mechanical, and geometric properties of bone. DESIGN, SETTING, AND OBJECTIVES: This randomized, double-blind, placebo-controlled outpatient study evaluated effects of once-monthly oral ibandronate on hip and lumbar spine BMD and calculated strength using quantitative computed tomography (QCT) with finite element analysis (FEA) and dual-energy x-ray absorptiometry (DXA) with hip structural analysis (HSA).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research